{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:50:10Z","timestamp":1792788610026,"version":"4.5.0"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japan Grant-in-Aid for Scientific Research","award":["20K08777"],"award-info":[{"award-number":["20K08777"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"\n Background<\/jats:title>\n Janus kinase (JAK) inhibitors (JAKis) are effective therapeutic agents against rheumatoid arthritis (RA). However, patients having RA with particular risk factors may have a higher incidence of adverse effects (AEs), including major cardiovascular events (MACE) and infections. In this multicenter cohort study, we aimed to clarify the risk factors affecting the drug retention of JAKis in patients with RA.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We retrospectively evaluated patients with RA who received their first JAKi (tofacitinib, baricitinib, upadacitinib, or filgotinib) at our institute. The clinical outcomes, including AEs, were recorded, particularly MACE and serious infections. The drug retention rates were analyzed using the Kaplan\u2013Meier method, and risk factors affecting drug retention rates were determined using a multivariable Cox regression hazards model.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Overall 184 patients with RA receiving their first use of baricitinib (57.6%), tofacitinib (23.9%), upadacitinib (12.0%), or filgotinib (6.5%) were included in this study. Fifty-six (30.4%) patients discontinued JAKi treatment owing to ineffectiveness (9.2%) or AEs, including infections (21.2%). The overall drug retention rates were significantly lower in patients treated with pan-JAKi than in those treated with JAK1 inhibitors (\n p<\/jats:italic>\n = 0.03). In the Cox regression model, the presence of baseline high RA disease activity, use of glucocorticoid and treatments with pan-JAKis were associated with reduced drug retention rates of JAKis (\n p<\/jats:italic>\n < 0.001,\n p<\/jats:italic>\n = 0.01 and 0.04, respectively). Pan-JAKi treated patients with high disease activity had significantly lower drug retention rates (\n p<\/jats:italic>\n < 0.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In a real-world setting, the drug retention rates of JAKis were reduced mainly by treatment discontinuation owing to AEs. Treatment with pan-JAKis and high baseline RA disease activity were identified as predictive factors for the discontinuation of JAKis. Lower drug retention rates were found in patients receiving pan-JAKis with high disease activity than in those without high disease activity.<\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pone.0306714","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T13:41:07Z","timestamp":1720705267000},"page":"e0306714","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Real-world comparative study of drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis"],"prefix":"10.1371","volume":"19","author":[{"given":"Kenji","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honoka","family":"Ebina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Sumichika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumpei","family":"Temmoku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzo","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-5622","authenticated-orcid":true,"given":"Kiyoshi","family":"Migita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"issue":"10055","key":"pone.0306714.ref001","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"JS Smolen","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"pone.0306714.ref002","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"JS Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"pone.0306714.ref003","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/annrheumdis-2021-220973","article-title":"EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis","volume":"81","author":"G Nagy","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"pone.0306714.ref004","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"AV Villarino","year":"2017","journal-title":"Nat Immunol"},{"issue":"6","key":"pone.0306714.ref005","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"JS Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"pone.0306714.ref006","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","author":"A Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"pone.0306714.ref007","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/JIR.S219586","article-title":"JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data","volume":"13","author":"R Harrington","year":"2020","journal-title":"J Inflamm Res"},{"issue":"4","key":"pone.0306714.ref008","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"SR Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0306714.ref009","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"D Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"5","key":"pone.0306714.ref010","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acr.21649","article-title":"Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice","volume":"64","author":"J Anderson","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"Suppl 2","key":"pone.0306714.ref011","doi-asserted-by":"crossref","first-page":"ii17","DOI":"10.1093\/rheumatology\/keaa823","article-title":"Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis","volume":"60","author":"E Mysler","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"pone.0306714.ref012","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Y Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"pone.0306714.ref013","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: the theory of relativity","volume":"18","author":"KL Winthrop","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 1","key":"pone.0306714.ref014","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","author":"M. Harigai","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"pone.0306714.ref015","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"L Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"pone.0306714.ref016","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","article-title":"JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"GE Fragoulis","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"pone.0306714.ref017","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/eji.202048922","article-title":"JAK inhibitors: Ten years after","volume":"51","author":"FR Spinelli","year":"2021","journal-title":"Eur J Immunol"},{"key":"pone.0306714.ref018","doi-asserted-by":"crossref","first-page":"110660","DOI":"10.1016\/j.intimp.2023.110660","article-title":"Current application status and structure-activity relationship of selective and non-selective JAK inhibitors in diseases","volume":"122","author":"T Li","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"pone.0306714.ref019","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"PG Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"pone.0306714.ref020","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story","volume":"83","author":"M Bonelli","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"pone.0306714.ref021","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1136\/annrheumdis-2020-219699","article-title":"Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting","volume":"80","author":"Y Miyazaki","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"pone.0306714.ref022","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001174","article-title":"Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland","volume":"6","author":"A Finckh","year":"2020","journal-title":"RMD Open"},{"issue":"3","key":"pone.0306714.ref023","doi-asserted-by":"crossref","first-page":"e063198","DOI":"10.1136\/bmjopen-2022-063198","article-title":"Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada","volume":"13","author":"M Movahedi","year":"2023","journal-title":"BMJ Open"},{"issue":"7","key":"pone.0306714.ref024","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/acr2.11432","article-title":"Time-Varying Association of Rheumatoid Arthritis Disease Activity to Subsequent Cardiovascular Risk","volume":"4","author":"K Yoshida","year":"2022","journal-title":"ACR Open Rheumatol"},{"issue":"2","key":"pone.0306714.ref025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","article-title":"Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician","volume":"20","author":"Z Szekanecz","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"pone.0306714.ref026","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"KL Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"pone.0306714.ref027","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/1744666X.2022.2039122","article-title":"Recent issues in JAK inhibitor safety: perspective for the clinician","volume":"18","author":"R. Fleischmann","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"pone.0306714.ref028","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of Janus Kinase inhibitor selectivity","volume":"58","author":"EH Choy","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 2","key":"pone.0306714.ref029","doi-asserted-by":"crossref","first-page":"ii24","DOI":"10.1093\/rheumatology\/keaa895","article-title":"The safety of JAK-1 inhibitors","volume":"60","author":"B Clarke","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"pone.0306714.ref030","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X231201047","article-title":"Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance","volume":"15","author":"GA Karpouzas","year":"2023","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"8","key":"pone.0306714.ref031","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/acr.24984","article-title":"Rheumatoid Arthritis Disease Activity and Hospitalized Infection in a Large US Registry","volume":"75","author":"H Yun","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0306714","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T13:41:31Z","timestamp":1720705291000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0306714"}},"subtitle":[],"editor":[{"given":"Masataka","family":"Kuwana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0306714","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]}}}